Headquartered in Marlborough, MA, Sepracor, Inc. (SEPR) is a research-based pharmaceutical company dedicated to treating and preventing human diseases through the discovery, development and commercialization of innovative pharmaceutical products that are directed toward serving unmet medical needs. Sepracor's drug development program has yielded an extensive portfolio of pharmaceutical compounds, with a focus on respiratory and central nervous system disorders. Sepracor currently has four products approved by the U.S. Food and Drug Administration (FDA) on the market: Xopenex, Xopenex HFA, Lunesta, and Brovana. Xopenex Inhalation Solution is a short-acting bronchodilator indicated for the treatment or prevention of bronchospasms in patients six years of age and older with reversible obstructive airway disease. The company's HFA-MDI (metered dose inhaler) for Xopenex was launched in the fourth quarter of 2005. Lunesta, launched in April 2005, is a breakthrough new product for insomnia and sleep disorder. Brovana launched in early 2007 and is approved for the treatment of chronic obstructive pulmonary disease (COPD). In 2006 Sepracor generated total revenue of $1.2 billion, an increase of 46% over 2005.
[edit] References
Edit Metric
Edit
History
Bookmark
